by McKesson Ventures | Aug 26, 2019 | Portfolio News
In a recent episode of the Oliver Wyman Health Podcast, Tom Robinson interviewed Aetion CEO Carolyn Magill about her unique career trajectory from the world of nuclear weapons to the world of health care, and how Aetion is partnering with organizations and companies...
by McKesson Ventures | Jun 27, 2019 | Portfolio News
Use of real-world evidence (RWE) in the pharmaceutical industry is becoming increasingly common. It aids the clinical development process and provides important data for pricing discussions once medicines have been approved. With that in mind, PharmaPhorum’s Richard...
by McKesson Ventures | Apr 12, 2019 | Portfolio News
The FDA, Brigham and Women’s Hospital, and Aetion are expanding their real-world evidence (RWE) demonstration to predict the results of seven ongoing FDA drug trials. The FDA drug or treatment trials are in Phase IV, meaning the drug or treatment is being tracked over...
by McKesson Ventures | Mar 21, 2019 | Portfolio News
In a paper recently published in the New England Journal of Medicine, researchers from McLean Hospital and Harvard Medical School said that certain drugs prescribed to teens and young adults with ADHD increase the risk of psychosis. The study, funded by the National...
by McKesson Ventures | Feb 13, 2019 | Portfolio News
Manhattan-based health technology company Aetion has added $27 million to its previously announced Series B round, bringing the total raised in the round to $63 million and the company’s total funding to $77 million. The company attracted strategic investment from...
